$BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC)$ Recently, I finally saw some great results from my investment in BeiGene, and I’m beyond thrilled! This stock has been performing exceptionally well lately. The company’s latest Q3 financial report showed a nearly 27% increase in revenue, reaching RMB 7.139 billion. Although they’re still reporting a net loss, such R&D investments are truly the cornerstone for future growth, especially for a biopharma company. BeiGene’s expanding product pipeline, particularly its innovation in oncology treatment, makes me really optimistic!
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
